Potential 18F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase

Nuclear Medicine and Biology

Volumn 28, Issue 4, 2001, Pages 359-374

  Bonasera, Thomas A ^a   Ortu, Giuseppina ^a   Rozen, Yulia ^a   Krais, Roman ^a   Freedman, Nanette M T ^b   Chisin, Roland ^a   Gazit, Aviv ^a   Levitzki, Alexander ^a   Mishani, Eyal ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Biodistribution; EGFr; Fluorine 18; PET; Quinazoline; Tyrosine kinase

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 [(3 FLUOROPHENYL)AMINO] 6,7 DIMETHOXYQUINAZOLINE F 18; 4 [(3,4 DICHLORO 6 FLUOROPHENYL)AMINO] 6,7 DIHYDROXYQUINAZOLINE F 18; 4 [(3,4 DICHLORO 6 FLUOROPHENYL)AMINO] 6,7 DIMETHOXYQUINAZOLINE F 18; 4 [(4 FLUOROPHENYL)AMINO] 6,7 DIMETHOXYQUINAZOLINE F 18; 4 [[3 FLUORO 5 (TRIFLUOROMETHYL)PHENYL]AMINO] 6,7 DIMETHOXYQUINAZOLINE F 18; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHOSPHORYLATION; CELL GROWTH; CHEMICAL REACTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PLASMA CLEARANCE; POSITRON EMISSION TOMOGRAPHY; RADIATION DOSE DISTRIBUTION;

ANIMALS; CELL DIVISION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLUORINE RADIOISOTOPES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PHOSPHORYLATION; QUINAZOLINES; RADIOPHARMACEUTICALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035016290     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(01)00200-1     Document Type: Article

References (28)

1. Recovery of cell subpopulations from human tumour xenografts following dissociation with different enzymes
2. Tyrosine kinase inhibitors, 8, An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD153035), a potent inhibitor of the epidermal growth factor receptor
3. 99mTc and in vivo localization following intracerebral injection into normal and glioma-bearing rats
4. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma
5. Sensitivity of new radiopharmaceuticals
6. 11C-labeled PD153035 in rats without and with neuroblastoma implants
7. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
8. Tyrphostins IV - Highly potent inhibitors of EGF receptor kinase, structure-activity relationship study of 4-anilidoquinazolines
9. Imaging of human tumor xenografts with an indium-111-labeled anti-epidermal growth factor receptor monoclonal antibody
10. Visualization by fluorescence of the binding and internalization of epidermal growth factor in human carcinoma cells A-431
11. Inhibition of the epidermal growth factor receptor tyrosine kinase by PD153035 in human A431 tumors in athymic nude mice
12. 111 In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors
13. Tyrosine kinase inhibition: An approach to drug development
14. Synthesis and in vitro evaluation of epidermal growth factor receptor tyrosine kinase inhibitors
15. Fluorinated EGFr-TK inhibitor-based tracers for PET
16. 18FTFMPP)
17. Radioiodinated epidermal growth factor receptor ligands as tumor probes, dramatic potentiation of binding to MDA-468 cancer cells in presence of EGF
18. Synthesis and biodistribution of new C-11 and F-18 labeled epidermal growth factor receptor ligands
19. 99mTc-labeled antihuman epidermal growth factor receptor antibody in patients with tumors of epithelial origin: Part III. Clinical trials safety and diagnostic efficacy
20. Tyrosine kinase inhibitors, 5, synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor
21. Tyrosine kinase inhibitors, 15, 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor
22. Tyrosine kinase inhibitors, 17, irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions
23. 18F]fluoroaniline as a synthon for epidermal growth factor receptor inhibitors for tumor imaging with PET
24. 131I-labelled epidermal growth factor in the pig visualized by dynamic scintigraphy
25. Effects of dextranation on the pharmacokinetics of short peptides, A PET study on mEGF